Revvity has introduced the CE-IVDR-certified GSP T1D 3plex kit, a multiplex dried blood spot assay for early type 1 diabetes screening in children, designed to support population-level programs.
Read More
Researchers at MUSC Hollings Cancer Center have developed the ADLiB liquid biopsy platform, which uses machine learning to prioritize lymphoma diagnosis, identifying high-risk patients with up to 95% accuracy.
Read More
A new study presented at ADLM 2026 shows a high-sensitivity biosensor can quantify the ESAT-6 protein in blood, distinguishing active tuberculosis from latent infection and other lung diseases.
Read More
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Read More
The automated assay identifies latent infections in routine laboratory settings with results available in less than 24 hours.
Read More